Save Sight Now Europe is funding a gene therapy project for Usher syndrome type 1B at the Institut reConnect in Paris, led by Sandrine Vitry and Aziz El-Amraoui.
LATEST
La Nit de la Visió 2026: tickets are now on sale
Saturday 21 November at the Recinte Modernista de Sant Pau, Barcelona. Tickets from €80. Everything we raise funds research to cure blindness in Usher 1B.
La Nit de la Visió 2025: €37,700 for Usher 1B research
The 3rd edition of La Nit de la Visió raised €37,700 at the Recinte Modernista de Sant Pau. Here is how the night went.
A quality test for every future Usher 1B treatment
SSNEU funded the first tool to see the MYO7A protein in lab-grown human retina. Save Sight Now and the Foundation Fighting Blindness are now taking it further.
The Night of Vision 2024: A Spotlight on Usher Syndrome
The annual La Nit de la Visió event, organized by Save Sight Now Europe, was once again a beacon of hope and progress in…
Nacuity Announces Positive Results for NP-1 Treatment. New Horizon for Usher Syndrome
Nacuity announces positive clinical results: oral treatment NPI-001 reduces photoreceptor loss by over 50% in Usher syndrome patientsThursday 11th September. A major step forward…
New Research Collaboration: Supporting Dr. Elvir Becirovic’s Innovative Gene Therapy Program for Usher Syndrome 1B
Save Sight Now Europe is proud to fund a cutting-edge research program led by Prof. Elvir Becirovic and his team at the University of…
Breakthrough in USH1B Research: Advancing MYO7A Therapy Development
Understanding MYO7A to Advance USH1B Therapies The goal of this project is twofold: 1. To gain a deeper understanding of the molecular causes of…
Spain Releases First Report on Rare Visual Diseases
Retina Murcia Association launches with its Research Group on Rare Visual Diseases (GISERV) the first Report on Rare Visual Diseases. Spain has published its…
We attended EURETINA 2024 in Barcelona
Save Sight Now Europe attended Euretina’24 in Barcelona from 19-22nd of September It was an honor to represent Usher Syndrome at the EURETINA 2024…
Collaborative Visit at L’Institut de la Vision, Paris
Save Sight Now Europe joined the team at L’Institut de la Vision, Paris, to collaborate and help accelerate treatments. Our recent visit to L’Institut…
AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B – First Patient Dosed
AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B and First Patient Dosed AAVantgarde has unveiled the design of its innovative LUCE-1 trial for…
RIWC 2024 (Retina International World Congress)
Championing Usher Syndrome: Highlights from RIWC24 in Dublin We are thrilled to share our experience at the Retina International World Congress 2024 (RIWC24) in…
ARVO 2024 (The Association for Research in Vision and Ophthalmology Conference)
Save Sight Now Europe has been at ARVO 2024 to Champion Advances in Retinal Disease Treatments From 4th to 10th May, Save Sight Now…
AAVantgarde Bio Unveils LUCE-1 Clinical Trial Design for Usher Syndrome type 1B Gene Therapy
AAVantgarde Bio Unveils Innovative LUCE-1 Clinical Trial Design (for USH1B) at Gene Therapy Summit Seattle, May 3, 2024 — AAVantgarde Bio, an Italian-based biotechnology…
Restoring hearing loss – leading advancement in OTOF gene-related deafness
First gene therapy treatment for a hereditary form of deafness in the USA The Children’s Hospital of Philadelphia successfully administered the first gene therapy…
UPDATE on David Gamm’s USH1B Research Program
SSNEU is collaborating with breakthrough research on gene editing for USH1B that offers hope for patients In a significant stride toward combating Usher Syndrome…
Unveiling Our Mission: Introducing the Foundation in Barcelona as We Expand to Spain!
Incredible experience at the Save Sight Now Europe | Foundation Usher Syndrome presentation event last Tuesday 7th November 2023, at the Old Estrella Damm…
Save Sight Now Europe Funds a program from the University of Wisconsin-Madison led by Dr. David Gamm: A Research to Study Gene Editing in Retinal Degeneration.
Save Sight Now Europe has awarded its first grant to the University of Wisconsin-Madison to fund research on gene editing in retinal degeneration. The…
Enrolling USH1B Patients for the Uni-Rare Natural History study launched by the Foundation Fighting Blindness: A critical and necessary step for upcoming clinical trials and future therapies.
Uni-Rare is a Natural History Study of vision loss progression. It is a critical and necessary step in supporting the approval of upcoming clinical…
OHSU confirms first nonhuman primate model of Usher Syndrome.
Researchers now have a model for testing gene therapy as a treatment for a leading cause of blindness-deafness. Save Sight Now has helped fund this…
The Foundation Fighting Blindness is launching it’s largest natural history study to date.
It will be for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes. It will include USH1B and Save Sight Now helped…
Save Sight Now Europe is now live!
We are starting a difficult journey, but one that comes from within, from our need to push and support, and from our will to…
Understanding Usher Syndrome Type 1B
Defining Characteristics & Research Significance Being born severe to profoundly deaf or gradually losing hearing, losing vision starting in infancy or later in adolescence,…
The first non-human primate USH1B model is created
Save Sight Now is funding groundbreaking research on Usher syndrome. For the last two years, Save Sight Now has supported a project that is…
